Stef P Menting
Overview
Explore the profile of Stef P Menting including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
219
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Huizen A, van der Kraaij G, Busard C, Ouwerkerk W, van den Reek J, Menting S, et al.
J Eur Acad Dermatol Venereol
. 2023 Apr;
37(9):1815-1824.
PMID: 37014287
Background: Anti-drug antibodies (ADA) are formed in patients treated with adalimumab (ADL). This might increase clearance of ADL, potentially causing a (secondary) non-response. Combination therapy of ADL and methotrexate (MTX)...
2.
van Huizen A, Sikkel R, Caron A, Menting S, Spuls P
J Dermatolog Treat
. 2022 Aug;
33(8):3104-3118.
PMID: 36043844
Background: Methotrexate (MTX) is a systemic treatment for plaque-type psoriasis. At the time of approval, no dose-ranging studies were performed. Nowadays, a uniform dosing regimen is lacking. This might contribute...
3.
van Huizen A, Menting S, Gyulai R, Iversen L, van der Kraaij G, Middelkamp-Hup M, et al.
JAMA Dermatol
. 2022 Mar;
158(5):561-572.
PMID: 35353175
Importance: A clear dosing regimen for methotrexate in psoriasis is lacking, and this might lead to a suboptimal treatment. Because methotrexate is affordable and globally available, a uniform dosing regimen...
4.
Ende T, Menting S, Ambarus C, van Oijen M, van Laarhoven H
Oncologist
. 2019 Mar;
24(4):e149-e153.
PMID: 30902915
Dermatological adverse events have frequently been reported after immune checkpoint inhibition. When an adverse event occurs during combination of immune checkpoint inhibition with chemotherapy, the question arises which agent is...
5.
Menting S, Coussens E, Pouw M, van den Reek J, Temmerman L, Boonen H, et al.
JAMA Dermatol
. 2015 Mar;
151(6):616-22.
PMID: 25807311
Importance: Adalimumab has proven to be effective in suppressing psoriasis disease activity and is administered in a standard dose. Objective: To establish a therapeutic range for adalimumab trough levels in...
6.
Menting S, Dekker P, Limpens J, Hooft L, Spuls P
Acta Derm Venereol
. 2015 Feb;
96(1):23-8.
PMID: 25721372
There is a range of methotrexate dosing regimens for psoriasis. This review summarizes the evidence for test-dose, start-dose, dosing scheme, dose adjustments, maximum dose and use of folic acid. A...
7.
Teunissen M, Munneke J, Bernink J, Spuls P, Res P, Te Velde A, et al.
J Invest Dermatol
. 2014 Mar;
134(9):2351-2360.
PMID: 24658504
Innate lymphoid cells (ILCs) are increasingly appreciated as important regulators of tissue homeostasis and inflammation. However, their role in human skin remains obscure. We found that healthy peripheral blood CD117(+)...
8.
Menting S, van Lumig P, de Vries A, van den Reek J, van der Kleij D, de Jong E, et al.
JAMA Dermatol
. 2013 Dec;
150(2):130-6.
PMID: 24352354
Importance: In a previously reported cohort of 29 patients with plaque-type psoriasis followed up for 24 weeks, clinically relevant antidrug antibody (ADA) to adalimumab was frequently found. Long-term data were...